<DOC>
	<DOCNO>NCT02869932</DOCNO>
	<brief_summary>The strategy neonatal screening Cystic Fibrosis France rely Immuno Reactive Trypsinogen ( IRT ) day 3/DNA analysis CF Elucigen 30 mutation kit/ IRT safety-net day 21 . This strategy significantly improve performance CF neonatal screening ( NNS ) term positive predictive value sensitivity reveal new difficulty . Up 85-90 % CF patient detect NNS program classical CF form positive sweat test 2 , 1 CF cause mutation remainder either 2 CFTR mutation least one non-CF cause mutation sweat test &lt; 60mmol/L 1 , 0 CFTR mutation intermediate sweat test value ≥ 30 et &lt; 60mmol/L raise diagnosis prognosis dilemma . Meanwhile vast majority cohort remain asymptomatic time , develop symptom prompt clinician maintain rigorous surveillance entire atypical cohort , whose modality vary lot among center country . This prospective multicenter study standardize assessment match cohort `` atypical '' CF versus `` classical '' CF 6 year age ( 60-65 case cohort ) aim evaluate pulmonary nutritional status , good define best monitoring follow-up , therapeutic management familial genetic counseling .</brief_summary>
	<brief_title>Prospective Study Phenotypic Expression Cystic Fibrosis ( CF ) Screened Positive Newborns With Atypical Form CF ( DPAM )</brief_title>
	<detailed_description>The strategy neonatal screening Cystic Fibrosis France rely Immuno Reactive Trypsinogen ( IRT ) day 3/DNA analysis CF Elucigen 30 mutation kit/ IRT safety-net day 21 . This strategy significantly improve performance CF neonatal screening ( NNS ) term positive predictive value sensitivity reveal new difficulty . Up 85-90 % CF patient detect NNS program classical CF form positive sweat test 2 , 1 CF cause mutation remainder either 2 CFTR mutation least one non-CF cause mutation sweat test &lt; 60mmol/L 1 , 0 CFTR mutation intermediate sweat test value ≥ 30 et &lt; 60mmol/L raise diagnosis prognosis dilemma . Meanwhile vast majority cohort remain asymptomatic time , develop symptom prompt clinician maintain rigorous surveillance entire atypical cohort , whose modality vary lot among center country . This prospective multicenter study standardize assessment match cohort `` atypical '' CF versus `` classical '' CF 6 year age ( 60-65 case cohort ) aim evaluate pulmonary nutritional status , good define best monitoring follow-up , therapeutic management familial genetic counseling .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>Atypical CF cohort : child identify trough newborn screen hypertrypsinemia , old 6 year age time inclusion carry ) 2 CFTR gene mutation CF30 kit least one R117H whatever value sweat test b ) 2 CFTR gene mutation CF30 kit sweat test chloride &lt; 60mmol/L c ) 1 0 mutation CF30 kit sweat test ≥ 30 &lt; 60mmol/L identification additional mutation comprehensive screen gene Classical CF cohort : child identify newborn screen hypertrypsinemia , match Atypical CF age sex possible diagnosed classical CF base sweat test &gt; 60 mmol/ L 0 , 1 2 CF cause gene mutation . • Drugs CFTR modulators interfere phenotypic expression disease .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>10 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>